Alflutinib (Furmonertinib) mesylate is is a potent inhibitor of EGFR. Alflutinib (Furmonertinib) mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Alflutinib (Furmonertinib) mesylate has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC).
性状
Solid
IC50 & Target[1][2]
EGFR
体外研究(In Vitro)
Alflutinib (Furmonertinib) mesylate is designed to inhibit EGFR active mutations as well as the T790M acquired resistant mutation. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, sealed storage, away from moistur 该产品在溶液状态不稳定,建议您现用现配,即刻使用。
ClinicalTrial
参考文献
[1]. Y. Shi, et al. P2.03-028 Third Generation EGFR Inhibitor AST2818 (Alflutinib) in NSCLC Patients with EGFR T790M Mutation: A phase1/2 Multi-Center Clinical Trial.
溶解度数据
In Vitro: DMSO : 5 mg/mL (7.52 mM; Need ultrasonic)配制储备液